LENSAR Inc
NASDAQ:LNSR

Watchlist Manager
LENSAR Inc Logo
LENSAR Inc
NASDAQ:LNSR
Watchlist
Price: 11.61 USD -0.17% Market Closed
Market Cap: 138.6m USD

LENSAR Inc
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

LENSAR Inc
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
LENSAR Inc
NASDAQ:LNSR
EPS (Diluted)
-$2
CAGR 3-Years
-9%
CAGR 5-Years
-15%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
EPS (Diluted)
$5
CAGR 3-Years
0%
CAGR 5-Years
17%
CAGR 10-Years
6%
Boston Scientific Corp
NYSE:BSX
EPS (Diluted)
$1
CAGR 3-Years
64%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
Stryker Corp
NYSE:SYK
EPS (Diluted)
$7
CAGR 3-Years
6%
CAGR 5-Years
10%
CAGR 10-Years
9%
Abbott Laboratories
NYSE:ABT
EPS (Diluted)
$8
CAGR 3-Years
21%
CAGR 5-Years
34%
CAGR 10-Years
10%
Intuitive Surgical Inc
NASDAQ:ISRG
EPS (Diluted)
$7
CAGR 3-Years
26%
CAGR 5-Years
21%
CAGR 10-Years
17%
No Stocks Found

LENSAR Inc
Glance View

Market Cap
138.6m USD
Industry
Health Care

LENSAR, Inc. engages in the development of femtosecond laser technology for refractive cataract surgery. The company is headquartered in Orlando, Florida and currently employs 110 full-time employees. The company went IPO on 2020-09-21. The firm is focused on designing, developing, and marketing femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company has developed the LENSAR Laser System to provide an alternative laser cataract treatment tool that allows the surgeon to better address astigmatism and improve visual outcomes. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. The company is also developing an integrated cataract treatment system, ALLY, which is designed to combine its existing femtosecond laser technology with phacoemulsification system into a single unit and allow surgeons to perform each of the critical steps in a cataract procedure in a single operating room using this device.

LNSR Intrinsic Value
8.22 USD
Overvaluation 29%
Intrinsic Value
Price

See Also

What is LENSAR Inc's EPS (Diluted)?
EPS (Diluted)
-2.7 USD

Based on the financial report for Dec 31, 2024, LENSAR Inc's EPS (Diluted) amounts to -2.7 USD.

What is LENSAR Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-15%

Over the last year, the EPS (Diluted) growth was -108%. The average annual EPS (Diluted) growth rates for LENSAR Inc have been -9% over the past three years , -15% over the past five years .

Back to Top